Status:
COMPLETED
Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid-Related Disorders
Eligibility:
All Genders
21-50 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate-dependence treatment.
Eligibility Criteria
Inclusion Criteria:
M/F ages 21-50. Meet DSM-IV criteria for opiate dependence. Agree to conditions of the study and sign informed consent.
Exclusion Criteria:
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
August 1 2000
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00000344
End Date
August 1 2000
Last Update
January 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Friends Research Institute
Los Angeles, California, United States, 90025